Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Open-Label, Single Ascending Dose Study To Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal CLG561 in Subjects With Advanced Age-Related Macular Degeneration

Trial Profile

A Multi-Center, Open-Label, Single Ascending Dose Study To Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal CLG561 in Subjects With Advanced Age-Related Macular Degeneration

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NOV 7 (Primary)
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Alcon

Most Recent Events

  • 24 Mar 2016 no of cohorts changed from 4 (50micro lit) to 5 cohorts (4 cohorts each of 40micro lit + 1 cohort of 100micro lit) as per ClinicalTrials.gov record.
  • 12 Nov 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
  • 12 Aug 2014 Planned End Date changed from 1 May 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top